Novo Nordisk’s NovoLog® (insulin aspart [rDNA origin] injection), FDA-Approved for Use in Pregnant Women with Type 1 Diabetes
NovoLog®, a product of Novo Nordisk A/S (NYSE: NVO) is a safe and effective treatment for pregnant women with Type 1 diabetes and their unborn children.
This fact has been further validated by the recent USFDA approval of NovoLog® (insulin aspart [rDNA origin] injection) for pregnancy Category B rating.
The Pregnancy Category B rating for NovoLog® indicates that adequate studies in pregnant women with Type 1 diabetes have demonstrated that NovoLog® does not increase risk to the unborn baby.
Previously classified under Category C rating, NovoLog® is a rapid-acting form of insulin for the treatment of people with diabetes mellitus for the control of hyperglycemia.
Offering convenient mealtime dosing and should be administered 5 to 10 minutes before a meal, NovoLog® enters the bloodstream quickly and begins working within minutes to lower blood glucose.
Find more details from the press release.
[Photo Credit: Novo Nordisk-U.S.]
